“East Asian Paradox”: Challenge for the Current Antiplatelet Strategy of “One-Guideline-Fits-All Races” in Acute Coronary Syndrome
- 596 Downloads
Clinical experiences have suggested that East Asians show the higher risk of warfarin-related intracranial hemorrhage compared with Westerners. Therefore, different target of the International Normalized Ratio (INR) in East Asians (1.6–2.6) has been proposed and adapted in clinical practice. In terms with antiplatelet therapy, recent evidence has supported the concept of “therapeutic level of platelet reactivity” to balance clinical efficacy and safety in patients undergoing percutaneous coronary intervention (PCI) or those with acute coronary syndrome (ACS). In line with the warfarin experiences, multiple clinical and pharmacodynamic data from East Asians have shown their different therapeutic level of platelet reactivity following PCI or ACS (“East Asian Paradox”). Furthermore, like most cardiovascular drugs, P2Y12 receptor blockers have marked interethnic differences in the pharmacokinetics and pharmacodynamics. The currently performed clinical trials evaluating the clinical efficacy and safety of potent P2Y12 inhibitors mostly don’t include enough number of East Asians to draw reliable conclusions. Therefore, dedicated research and guideline(s) for East Asians are required before we can apply Western recommendations for potent P2Y12 inhibitors in East Asian population. It is a time to consider the paradigm shift from “one-guideline-fits-all races” to “race-tailored antiplatelet therapy” in treating ACS patients.
KeywordsRace Warfarin P2Y12 inhibitor Acute coronary syndrome Thrombogenicity East Asian Paradox Antiplatelet strategy
This study was partly supported by grants from Institute of the Health Sciences, Gyeongsang National University.
Compliance with Ethics Guidelines
Conflict of Interest
Young-Hoon Jeong has received honoraria for lectures from Sanofi-Aventis, Daiichi Sankyo/Lilly, AstraZeneca, Haemonetics, and Otsuka; and research grants or support from Han-mi Pharmaceuticals, Boehringer-Ingelheim, Otsuka, Accumetrics, and Haemonetics.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58:2550–83.CrossRefGoogle Scholar
- 2.•Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261–73. Good review for the recent evidence of “therapeutic level of platelet reactivity” during P2Y 12 receptor inhibitors. Google Scholar
- 7.Ogawa S, Aizawa Y, Atarashi H, Inoue H, Okumura K, Kamakura S. Guidelines for pharmacotherapy of atrial fibrillation. Circ J. 2008;72(Suppl IV):1639–58.Google Scholar
- 8.Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke. 2000;31:817–21.PubMedCrossRefGoogle Scholar
- 9.•Scott SA, Sangkuhl K, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94:317–23. Good review for updated pharmacogenetic information of clopidogrel treatment.PubMedCentralPubMedCrossRefGoogle Scholar
- 10.Jeong YH, Abadilla KA, Tantry US, et al. Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2 N3 study. J Thromb Haemost. 2013;11:1194–7.PubMedCrossRefGoogle Scholar
- 13.Zhang HZ, Kim MH, Jeong YH. Predictive values of post-clopidogrel platelet reactivity assessed by different platelet function tests on ischemic events in East Asian patients treated with PCI. Platelets. 2013. [Epub ahead of print].Google Scholar
- 14.Ko YG, Suh JW, Kim BH, et al. Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. Am Heart J. 2011;161:383–90.PubMedCrossRefGoogle Scholar
- 15.Suh JW, Lee SP, Park KW, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol. 2011;57:280–9.PubMedCrossRefGoogle Scholar
- 17.Jin HY, Yang TH, Kim DI, et al. High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting. Int J Cardiol. 2013;167:1877–81.PubMedCrossRefGoogle Scholar
- 19.•Mak KH, Bhatt DL, Shao M, et al. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Am Heart J. 2009;157:658–65. Important clinical data showing different clinical efficacy and safety across the races in high-risk patients during aspirin monotherapy or dual antiplatelet therapy.PubMedCrossRefGoogle Scholar
- 23.•Kumar RS, Douglas PS, Peterson ED, et al. Effect of race and ethnicity on outcomes with drug-eluting and bare metal stents: results in 423,965 patients in the linked National Cardiovascular Data Registry and centers for Medicare & Medicaid services payer databases. Circulation. 2013;127:1395–403. Important large scale clinical data to compare clinical outcomes following percutaneous coronary intervention between the races.PubMedCrossRefGoogle Scholar
- 25.Jeong YH. Correlation between platelet reactivity and type of post-discharge bleeding events in patients undergoing percutaneous coronary intervention: results of the ACCEL-BLEED study. J Am Coll Cardiol. 2011;58:B221.Google Scholar
- 33.Ang L, Thani KB, Ilapakurti M, Lee MS, Palakodeti V, Mahmud E. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. J Am Coll Cardiol. 2013;61:23–34.PubMedCrossRefGoogle Scholar
- 36.Schoos MM, Kelbæk H, Kofoed KF, et al. Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. Am J Cardiol. 2011;107:1597–603.PubMedCrossRefGoogle Scholar
- 37.•Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19. Large scale clinical data to show the benefit of new oral Xa inhibitor in addition to dual antiplatelet therapy on thrombotic events in acute coronary syndrome patients.PubMedCrossRefGoogle Scholar
- 45.••Gorog DA, Yamamoto J, Saraf S, et al. First direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: possible relationship to the “Japanese paradox”. Int J Cardiol. 2011;152:43–8. The first study to directly compare the level of thrombotic status and fibrinolytic activity between East Asians and Westerners.PubMedCrossRefGoogle Scholar
- 50.•Small DS, Kothare P, Yuen E, et al. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. Eur J Clin Pharmacol. 2010;66:127–35. Comprehensive study comparing the pharmacokinetic and pharmacodynamic data during prasugrel treatment between East Asians and Caucasians.PubMedCrossRefGoogle Scholar
- 57.Jin HY, Yang TH. Randomized comparisons of the platelet inhibitory effect of clopidogrel and two doses of prasugrel in patients receiving antiplatelet therapy after coronary stent implantation. Daejeon, Korea: Korean Society of Cardiology. 2012.Google Scholar
- 58.••Saito S, Isshiki T, Ogawa H, Kimura T, Yokoi H, Nakamura M. PRASugrel compared to clopidogrel For Japanese PatIenTs with ACS undergoing PCI (PRASFIT-ACS) study. Presented at Late Breaking Clinical Trials Session at the 77th Annual Scientific Meeting of the Japanese Circulation Society; March 16, 2012, the Pacifico: Yokohama. The first study to compare the clinical efficacy and safety of low-dose prasugrel vs standard-dose clopidogrel in East Asians with acute coronary syndrome. Google Scholar
- 59.••PHILO Trial. A randomized, double-blind, double-dummy, parallel group, international, multicenter, Phase 3 study to assess the efficacy and safety of ticagrelor vs clopidogrel on top of low-dose acetylsalicylic acid in Asian/Japanese patients with non-ST or ST-elevation ACS for whom PCI is planned. Available from: http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/D5130C00027. Accessed 19 Nov 2013. The first study to compare the clinical efficacy and safety of guideline-recommended ticagrelor vs standard-dose clopidogrel in East Asians with acute coronary syndrome.